Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acidil is an over-the-counter homeopathic medicinal product manufactured by Boiron, designed to alleviate symptoms associated with gastroesophageal reflux disease (GERD), such as heartburn, acid indigestion, and dyspepsia. It contains a specific combination of four homeopathic active ingredients: *Abies nigra* 4C, *Carbo vegetabilis* 4C, *Nux vomica* 4C, and *Robinia pseudoacacia* 4C. The product was evaluated in a pilot randomized, double-blind, placebo-controlled trial led by Beth Israel Deaconess Medical Center and Harvard Medical School, which utilized a 2x2 factorial design to study the effects of the supplement alongside different patient-provider interaction styles. Acidil is typically administered as meltaway tablets that dissolve under the tongue and is marketed for the relief of occasional heartburn and upset stomach.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Acidil.